FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer

August 1, 2017 – The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The approval is based on results from the phase II CheckMate-142 trial, in which the overall response rate (ORR) was 28% in mCRC patients … (leggi tutto)